HOME >> BIOLOGY >> NEWS
Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT

Tampa, FL (June 24, 2005)-H. Lee Moffitt Cancer Center & Research Institute, working in partnership with the University of South Florida (USF), has discovered a new use for an old, previously discredited anti-cancer drug that could add another weapon in the arsenal against several cancers, including tumors of the breast, ovary, colon, skin and prostate.

The compound, tricirbine, was tested at various cancer centers from 1982 to 1996 and found to inhibit some cancers, but researchers failed to determine why. The Moffitt-USF team discovered that tricirbine works only against tumors in which the cancer-causing Akt protein is abundant and/or abnormally active.

"These tumors are addicted to hyperactive Akt and cannot survive without it," explains Sad Sebti, Ph.D., Moffitt's Manuel and Adeline Garcia Professor, Leader of the Drug Discovery Program and Associate Director of Moffitt Research Institute. "What we discovered is a tailored therapy for tumors with a specific molecular signature."

Resurrecting tricirbine may be promising for patients with ovarian cancer, for instance, because "40 percent of women with ovarian cancer have tumors with high levels of active Akt," according to Sebti.

"To our knowledge, this is the first Akt inhibitor headed toward clinical trials," said Jin Cheng, MD, PhD, USF Professor of Pathology and Interdisciplinary Oncology.

Cheng and Sebti's study results were published in the journal Cancer Research.

VioQuest Pharmaceuticals Inc. (VQPH) of New Jersey is acquiring the licensing rights to the compound from USF through its merger with Greenwich Therapeutics Inc. and is planning clinical trials with Moffitt. The trials are expected to start within six to eight months. Patients will be selected for the trials based on whether their tumors have hyperactive Akt, which can be determined by a simple slide-stain test of tumor tissue.

Because tricirbine has previously been investigated in humans
'"/>

Contact: Andrea Brunais
MediaRelations@moffitt.usf.edu
813-632-1478
University of South Florida Health
24-Jun-2005


Page: 1 2

Related biology news :

1. Bursts of waves drive immune system soldiers toward invaders
2. A decisive step toward a cure for insulin dependent diabetes
3. Cloned pigs help scientists towards a breakthrough in Alzheimers
4. Paving the way toward a vaccine against Alzheimers disease
5. Latest strategies for moving research toward a cure for diabetes explored at global scientific forum
6. Progress toward a targeted therapy for a specific form of leukemia
7. Tiny clue reveals new path toward heart disease
8. Progress toward artificial photosynthesis?
9. MIT engineer works toward clean water, more
10. Sperm proteome gives tantalizing glimpse towards the origin of sex
11. Stretching bone marrow stem cells pushes them towards becoming blood vessel

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... Md. (PRWEB) , ... October 11, 2018 , ... ... economy is the vision behind the National Institute for Innovation in Manufacturing Biopharmaceuticals ... array of projects designed to advance biopharmaceutical manufacturing and workforce development in the ...
(Date:10/5/2018)... ... October 04, 2018 , ... ... communications and collaboration solutions, was present at Microsoft Ignite 2018, in Orlando, Florida, ... solutions. , Microsoft issued a statement about the new direction of Skype for ...
(Date:10/5/2018)... PRINCETON, N.J. (PRWEB) , ... October 04, 2018 , ... ... will be exhibiting at the CDISC U.S. Interchange in Bethesda, MD on October 8-12, ... (BBSW), in Foster City, CA on November 5-6, 2018. , CDISC Interchanges are ...
Breaking Biology News(10 mins):
(Date:9/28/2018)... ... September 28, 2018 , ... GlycoMark®, Inc. has ... of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent ... promote and offer the GlycoMark test to its network of physicians through its ...
(Date:9/27/2018)... ... September 26, 2018 , ... NDA ... Cimler, a senior quality, regulatory, and in vitro diagnostic device expert with more ... industry has joined the firm as an Expert Consultant. Her experience includes leadership ...
(Date:9/27/2018)... ... September 26, 2018 , ... Medable was named DPharm ... build the first human digitome, a digital representation of human health and disease, ... integration of all data sources. Dr. Michelle Longmire, Co-Founder and CEO of Medable, ...
(Date:9/27/2018)... ... September 27, 2018 , ... This past weekend ... SureAdhere Mobile Technology, Inc. announced they will formally merge companies and integrate their ... tuberculosis (TB) and other diseases. These two social enterprise corporations, both of which ...
Breaking Biology Technology:
Cached News: